Clinical trials: Prophylaxis of Venous Thromboembolism
Thrombosis, Venous
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)
This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).
- Trial name
- NCT00320398
- Testing
- Fondaparinux
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Quality of Health Care
Prevention of Venous Thromboembolism Disease in Emergency Departments
The appropriate use of thromboprophylaxis in medical patients admitted to hospital can substantially reduce the overall burden of disease due to venous thromboembolism.
- Trial name
- PREVENU (NCT01212393)
- Testing
- reminders
- Where
- 23 sites in France
- Volunteers
- 20,000 people
- Sponsor
- University Hospital, Angers
Postpartum, VTE Prophylaxis
Excretion of Rivaroxaban in Human Breast Milk
The purpose of this study is to investigate the distribution of rivaroxaban into human milk at both therapeutic and prophylactic doses, and over time with repeated dosing.
- Conditions
- Postpartum, VTE Prophylaxis, VTE (Venous Thromboembolism), Rivaroxaban
- Trial name
- LACT (NCT06831474)
- Testing
- Rivaroxaban 10 MG Oral Tablet, Rivaroxaban 20 MG Oral Tablet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Jefferson University
Cancer, VTE (Venous Thromboembolism)
DOAC - Dosing Options in AntiCoagulation Prophylaxis
Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death.
- Trial name
- DOAC (NCT07005024)
- Testing
- Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
- Where
- United States
- Volunteers
- 996 people
- Sponsor
- University of Vermont
Circulatory Disease
Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
This study is a multicenter, randomized, open-label, positive-controlled Phase II clinical study to evaluate the efficacy and safety of H001 capsules in the prevention of venous thromboembolism (VTE) in subjects undergoing Total…
- Trial name
- NCT06963320
- Testing
- H001 Capsule 200mg-qd, Enoxaparin Sodium Injection, H001 Capsule 300mg-qd
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
The primary objective was to compare the efficacy of Semuloparin sodium (AVE5026) with Enoxaparin for the prevention of Venous Thromboembolic Events [VTE] in patients undergoing elective knee replacement surgery.
- Trial name
- SAVE-KNEE (NCT00718224)
- Testing
- Semuloparin sodium, Enoxaparin
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 1,150 people
- Sponsor
- Sanofi
Venous Thromboembolism
An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®
The objective of this study is to observe the safety, tolerability, and compliance in the use of Fragmin® for prolonged thromboprophylaxis in post-surgery high-risk orthopedic patients.
- Trial name
- NCT01046903
- Testing
- Fragmin® (Dalteparin Sodium)
- Volunteers
- 503 people
- Sponsor
- Pfizer